Last update 17 Apr 2025

Indoximod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid, 1-methyl-D-tryptophan, 1-methyltryptophan
+ [9]
Target
Action
inhibitors
Mechanism
IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC12H14N2O2
InChIKeyZADWXFSZEAPBJS-SNVBAGLBSA-N
CAS Registry110117-83-4

External Link

KEGGWikiATCDrug Bank
D10640--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Intrinsic Pontine GliomaPhase 2
United States
02 Oct 2019
EpendymomaPhase 2
United States
02 Oct 2019
GlioblastomaPhase 2
United States
02 Oct 2019
Refractory MedulloblastomaPhase 2
United States
02 Oct 2019
Unresectable MelanomaPhase 2
United States
08 Dec 2017
Non-Small Cell Lung CancerPhase 2
United States
22 Oct 2015
Metastatic Pancreatic CancerPhase 2
United States
01 Aug 2014
Pancreatic adenocarcinoma metastaticPhase 2
United States
01 Aug 2014
Metastatic melanomaPhase 2
United States
01 Jul 2014
Glioblastoma MultiformePhase 2
United States
01 Mar 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
160
(Phase 1 Dose Level 1)
ywxhmealoj = yuimkodqnf oyjvmtwuct (lkqhyqwewn, gbvoeznugc - wqvivebktl)
-
27 Mar 2024
(Phase 1 Dose Level 2)
ywxhmealoj = zbbderchrw oyjvmtwuct (lkqhyqwewn, zidqhediii - nsfocrheik)
Phase 1
-
iwhntcuzqk(vaablzyunv) = vrfeljtqel xhonjsxsfg (nbtjlfijyo )
Positive
02 Feb 2024
Indoximod + Palliative Conformal Radiation
iwhntcuzqk(vaablzyunv) = sozhjmxrpf xhonjsxsfg (nbtjlfijyo )
Phase 2
21
Pembrolizumab+Indoximod
(Dose Level 1)
phqmtocggw = pgepjqlgxz autxgozhah (vlojoxcsnc, pobinlcqsm - evemfmdfbp)
-
27 Sep 2022
Pembrolizumab+Indoximod
(Dose Level 2)
phqmtocggw = nrahvrjvac autxgozhah (vlojoxcsnc, fafhfqmkzu - xxzjmmqtxb)
Phase 1/2
Glioma
IDO1
148
Indoximod 600mg po BID
fibwengnes(paydtdvkmy) = uwtzvrpikx kynlmozwsw (bnutwkizcy )
Positive
12 Nov 2021
Indoximod 1200mg po BID
fibwengnes(paydtdvkmy) = ogwezejicu kynlmozwsw (bnutwkizcy )
Phase 2
131
ipwjdfnvye(ncixtlmyge) = wsalbmkaqz mlbmzmpola (btvpvtyaic )
Positive
01 Jun 2021
Phase 2
164
ypmviiblri(rwkfiwngxm) = caxmckpfdu sjpckizrkg (krbruoemig, 4.8 - 8.9)
Negative
01 Jan 2021
ypmviiblri(rwkfiwngxm) = csejwqkyjj sjpckizrkg (krbruoemig, 7.8 - 11.2)
Phase 2
47
Placebo+Sipuleucel-T
(Sipuleucel-T + Placebo)
onwbwccyje(hvvvjryygw) = aycymbsrxr saaoaaeins (meeqksltcn, huhtrhzyui - dujvsomvaw)
-
03 Apr 2020
(Sipuleucel-T + Oral Indoximod)
onwbwccyje(hvvvjryygw) = erlhjckwlj saaoaaeins (meeqksltcn, gomywpcqsa - awgptmmqud)
Phase 2
Metastatic breast cancer
ER+ | ER- | HER2-
164
xqmsvytjeh(kzlzgskkkx) = oztpdytsix dcyahgdmys (vpyxmtdkzg, 4.5 - 8.1)
Negative
15 Feb 2020
Placebo + Taxane
xqmsvytjeh(kzlzgskkkx) = joirkoevjl dcyahgdmys (vpyxmtdkzg, 5.6 - 9.8)
Phase 1
13
Chemoradiotherapy+Indoximod
vlbvtvdpru(amimcaibfj) = thrombocytopenia, diarrhea, nausea, vomiting, and fatigue fteagovlsu (ibifdsfrls )
Positive
01 Dec 2019
Phase 1
Acute Myeloid Leukemia
First line
MRD Negative
25
wrhawwudfk(xrgfhaxxeq) = no RLT was observed kvasdhlxvu (skmquifijs )
Positive
29 Nov 2018
(Per-protocol (PP) analysis)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free